Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Stoke Therapeutics (STOK) Receivables - Net (2024 - 2025)

Stoke Therapeutics has reported Receivables - Net over the past 2 years, most recently at $5.9 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 255.88% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $5.9 million, up 255.88%, while the annual FY2025 figure was $5.9 million, 255.88% up from the prior year.
  • Receivables - Net for Q4 2025 was $5.9 million at Stoke Therapeutics, down from $9.2 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $9.2 million in Q3 2025 and troughed at $1.7 million in Q4 2024.